Jane Street’s Galectin Therapeutics GALT Stock Holding History

Jane Street’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$72.4K	Buy	+15,600	New	+$40.4K	﹤0.01%	10773
2025 Q1	–	Sell	-70,100	Closed	-$90.4K	–	9809
2024 Q4	$90.4K	Buy	+70,100	New	+$168K	﹤0.01%	8793

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Jane Street's GALT Position: Q2 2026 in Review

Jane Street sold out of Galectin Therapeutics (GALT) in Q2 2026, closing a stake of 194,868 shares — an estimated $505K sold.

Jane Street first reported a position in GALT in Q3 2013 and held it in 15 quarters. The position peaked at $1.58M in Q2 2025. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Jane Street reported no remaining Galectin Therapeutics position as of Q2 2026 after selling out during the quarter.
Jane Street sold 194,868 Galectin Therapeutics shares in Q2 2026, an estimated $505K.
Jane Street first reported a position in Galectin Therapeutics in Q3 2013 and held it in 15 quarters.
Jane Street's Galectin Therapeutics position peaked at $1.58M in Q2 2025.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Jane Street's 13F filing for Q2 2026, filed 14 Aug 2026.